Create your Personal Health Record and unlock support built around you
- Treatments and trials you qualify for
- Education for your stage of care
- Financial support for your medications
- Solutions to your side effects
Menin Inhibitors in AML: Moving Forward with Ziftomenib & Beyond #AML | EHA 2026
HealthTreeDescription
Dr. Eytan Stein, Chief of Leukemia at Memorial Sloan Kettering Cancer Center, discusses the exciting advances with menin inhibitors in acute myeloid leukemia.
APPROVED MENIN INHIBITORS:
Two menin inhibitors now approved for relapsed/refractory AML patients with:
- KMT2A mutations/rearrangements
- NPM1 mutations
THE NEXT FRONTIER:
Instead of waiting for relapse, researchers are combining menin inhibitors with standard chemotherapy in newly diagnosed patients.
KEY ADVANCEMENT - ZIFTOMENIB + INTENSIVE CHEMOTHERAPY:
- For NPM1-mutated AML
- Extremely high remission rates
- 90% survival at ~2 years
- Represents the field's future direction
OVERCOMING RESISTANCE:
Researchers have identified that some patients develop resistance mutations to menin inhibitors. A new clinical trial combines:
- Menin inhibitors
- Mezigdomide (a drug from multiple myeloma)
- This combination appears to overcome resistance
WHAT'S NEXT:
Results from resistance-overcoming trials expected within 1-2 years. The future of menin inhibitors looks very promising.
Learn more: https://linktr.ee/HealthTreeUniversity
TIMESTAMPS:
0:00 Introduction
0:11 Menin Inhibitors Excitement
0:18 Two Approved Menin Inhibitors
0:26 Moving to Front-Line Therapy
0:44 Ziftomenib + Chemotherapy
1:00 Impressive Survival Results
1:08 The Future: Combination Approach
1:26 The Resistance Problem
1:34 Overcoming Resistance Strategy
1:52 What's Next for Menin Inhibitors
#AML #MeninInhibitors #Ziftomenib #NPM1 #ClinicalTrial